Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Halquinol is a non-antibiotic antimicrobial mixture belonging to the quinoline family, specifically composed of 5,7-dichloro-8-quinolinol (approximately 60%), 5-chloro-8-quinolinol (approximately 30%), and 7-chloro-8-quinolinol (approximately 10%). It is primarily utilized in veterinary medicine as a feed additive for swine and poultry to promote growth and control enteric infections. Halquinol acts locally within the gastrointestinal tract and is not significantly absorbed into the systemic circulation. Its mechanism of action involves the chelation of essential metal ions required for microbial enzyme activity and a direct anti-peristaltic effect on the intestinal smooth muscle, which increases the transit time of digesta and improves nutrient absorption. It is effective against a wide range of Gram-positive and Gram-negative bacteria, as well as fungi and protozoa like *Entamoeba histolytica*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on halquinol.